Lantern Pharma (NASDAQ: LTRN) will host a webcast on Thursday, November 13, 2025, at 9 a.m. ET to review third-quarter operating and financial results and provide updates on the company's artificial intelligence platform development. President and CEO Panna Sharma will lead the presentation alongside other management team members to discuss quarterly performance, clinical trial progress, and upcoming milestones for the company's AI and machine learning initiatives.
The company represents a growing trend in biotechnology where artificial intelligence is fundamentally transforming cancer drug discovery and development. Lantern Pharma's proprietary RADR platform leverages over 200 billion oncology-focused data points and utilizes more than 200 advanced machine learning algorithms to address significant challenges in oncology drug development. This AI-driven approach aims to reduce both the cost and timeline traditionally associated with bringing new cancer therapies to market.
Lantern Pharma's pipeline includes multiple development programs spanning various cancer indications, including both solid tumors and blood cancers, along with an antibody-drug conjugate program. The company currently has a Phase 2 clinical program and multiple Phase 1 clinical trials underway. According to company estimates, their AI-driven pipeline of innovative product candidates has a combined annual market potential exceeding $15 billion USD, representing significant commercial opportunity in the oncology space.
The company's approach to drug development emphasizes the potential for life-changing therapies that could benefit hundreds of thousands of cancer patients worldwide. By harnessing artificial intelligence to identify and develop targeted cancer therapies more efficiently, Lantern Pharma aims to address what it describes as "billion-dollar, real-world problems" in oncology drug development. The upcoming webcast will provide investors and stakeholders with crucial updates on how these AI-driven initiatives are progressing and their impact on the company's financial and operational performance.
For additional information about the company, investors can access the latest news and updates in the company's newsroom at https://ibn.fm/LTRN. The webcast represents an important opportunity for the investment community to gain insight into how artificial intelligence is reshaping cancer drug development and creating new possibilities for treating various forms of cancer through more targeted and efficient therapeutic approaches.
